PIK3R3 and lymphoma: Promisingly, in long‐term in vivo xenograft and syngeneic studies across multiple models and at elevated T‐cell doses, CARD11‐PIK3R3 exhibited no signs of lymphoma relapse up to 418 days post‐overdose of T‐cell transplantation.